{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:20:18Z","timestamp":1791901218760,"version":"4.3.4"},"reference-count":86,"publisher":"Bentham Science Publishers Ltd.","issue":"7","funder":[{"DOI":"10.13039\/501100019081","name":"Science and Technology Innovation Program of Hunan Province, China","doi-asserted-by":"publisher","award":["2021RC2023"],"award-info":[{"award-number":["2021RC2023"]}],"id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M703638"],"award-info":[{"award-number":["2021M703638"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201557"],"award-info":[{"award-number":["82201557"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Congenital myasthenic syndromes (CMS) refer to a series of inherited disorders\ncaused by defects in various proteins. Mutation in the collagen-like tail subunit of asymmetric acetylcholinesterase\n(COLQ) is the second-most common cause of CMS. However, data on pharmacological\ntreatments are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>In this study, we reviewed related reports to determine the most appropriate pharmacological\nstrategy for CMS caused by COLQ mutations. A literature review and meta-analysis were also performed.\nPubMed, MEDLINE, Web of Science, and Cochrane Library databases were searched to identify\nstudies published in English before July 22, 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 42 studies including 164 patients with CMS due to 72 different COLQ mutations\nwere selected for evaluation. Most studies were case reports, and none were randomized clinical trials.\nOur meta-analysis revealed evidence that \u03b2-adrenergic agonists, including salbutamol and ephedrine,\ncan be used as first-line pharmacological treatments for CMS patients with COLQ mutations, as 98.7%\nof patients (74\/75) treated with \u03b2-adrenergic agonists showed positive effects. In addition, AChEIs\nshould be avoided in CMS patients with COLQ mutations, as 90.5% (105\/116) of patients treated with\nAChEIs showed either no or negative effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>(1) \u03b2-adrenergic agonist therapy is the first pharmacological strategy for treating CMS\nwith COLQ mutations. (2) AChEIs should be avoided in patients with CMS with COLQ mutations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1570159x21666230126145652","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T01:52:58Z","timestamp":1674784378000},"page":"1594-1605","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacological Treatments for Congenital Myasthenic Syndromes\nCaused by\n                    <i>COLQ<\/i>\n                    Mutations"],"prefix":"10.2174","volume":"21","author":[{"given":"Shuai","family":"Shao","sequence":"first","affiliation":[{"name":"Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China\nXiangya"},{"name":"Xiangya School of Medicine, Central South University, Changsha, Hunan province, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanzhong","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China\nXiangya"},{"name":"Xiangya School of Medicine, Central South University, Changsha, Hunan province, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Fang","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0301-0082(00)00055-1","volume":"64","author":"Wood S.J.","year":"2001","unstructured":"Wood S.J.; Slater C.R.; Safety factor at the neuromuscular junction. Prog Neurobiol 2001,64(4),393-429","journal-title":"Prog Neurobiol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"8058","DOI":"10.3390\/ijms22158058","volume":"22","author":"Iyer S.R.","year":"2021","unstructured":"Iyer S.R.; Shah S.B.; Lovering R.M.; The neuromuscular junction: Roles in aging and neuromuscular disease. Int J Mol Sci 2021,22(15),8058","journal-title":"Int J Mol Sci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S1474-4422(14)70201-7","volume":"14","author":"Engel A.G.","year":"2015","unstructured":"Engel A.G.; Shen X.M.; Selcen D.; Sine S.M.; Congenital myasthenic syndromes: Pathogenesis, diagnosis, and treatment. Lancet Neurol 2015,14(4),420-434","journal-title":"Lancet Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1111\/jcmm.17417","volume":"26","author":"Huang K.","year":"2022","unstructured":"Huang K.; Duan H.Q.; Li Q.X.; Luo Y.B.; Bi F.F.; Yang H.; Clinicopathological\u2010genetic features of congenital myasthenic syndrome from a Chinese neuromuscular centre. J Cell Mol Med 2022,26(14),3828-3836","journal-title":"J Cell Mol Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.nmd.2021.07.400","volume":"31","author":"Ramdas S.","year":"2021","unstructured":"Ramdas S.; Beeson D.; Congenital myasthenic syndromes: Where do we go from here? Neuromuscul Disord 2021,31(10),943-954","journal-title":"Neuromuscul Disord"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.nmd.2017.08.003","volume":"27","author":"Natera-de Benito D.","year":"2017","unstructured":"Natera-de Benito D.; T\u00f6pf A.; Vilchez J.J.; Gonz\u00e1lez-Quereda L.; Dom\u00ednguez-Carral J.; D\u00edaz-Manera J.; Ortez C.; Bestu\u00e9 M.; Gallano P.; Dusl M.; Abicht A.; M\u00fcller J.S.; Senderek J.; Garc\u00eda-Ribes A.; Muelas N.; Evangelista T.; Azuma Y.; McMacken G.; Paipa Merchan A.; Rodr\u00edguez C.P.M.; Camacho A.; Jim\u00e9nez E.; Miranda-Herrero M.C.; Santana-Artiles A.; Garc\u00eda-Campos O.; Dominguez-Rubio R.; Oliv\u00e9 M.; Colomer J.; Beeson D.; Lochm\u00fcller H.; Nascimento A.; Molecular characterization of congenital myasthenic syndromes in Spain. Neuromuscul Disord 2017,27(12),1087-1098","journal-title":"Neuromuscul Disord"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/jnnp.2009.177816","volume":"81","author":"Mihaylova V.","year":"2010","unstructured":"Mihaylova V.; Scola R.H.; Gervini B.; Lorenzoni P.J.; Kay C.K.; Werneck L.C.; Stucka R.; Guergueltcheva V.; von der Hagen M.; Huebner A.; Abicht A.; M\u00fcller J.S.; Lochm\u00fcller H.; Molecular characterisation of congenital myasthenic syndromes in Southern Brazil. J Neurol Neurosurg Psychiatry 2010,81(9),973-977","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1136\/archdischild-2013-304788","volume":"99","author":"Parr J.R.","year":"2014","unstructured":"Parr J.R.; Andrew M.J.; Finnis M.; Beeson D.; Vincent A.; Jayawant S.; How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Arch Dis Child 2014,99(6),539-542","journal-title":"Arch Dis Child"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejpn.2020.02.002","volume":"26","author":"Troha Gergeli A.","year":"2020","unstructured":"Troha Gergeli A.; Neubauer D.; Golli T.; Butenko T.; Loboda T.; Maver A.; Osredkar D.; Prevalence and genetic subtypes of congenital myasthenic syndromes in the pediatric population of Slovenia. Eur J Paediatr Neurol 2020,26,34-38","journal-title":"Eur J Paediatr Neurol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jns.2019.10.1310","volume":"405","author":"Joshi D.","year":"2019","unstructured":"Joshi D.; Patil S.; Dash P.; Mishra V.; Chaurasia R.; Pathak A.; Congenital myathenic syndrome associated with COLQ mutation: An interesting report. J Neurol Sci 2019,405,266","journal-title":"J Neurol Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/acn3.51346","volume":"8","author":"Zhao Y.","year":"2021","unstructured":"Zhao Y.; Li Y.; Bian Y.; Yao S.; Liu P.; Yu M.; Zhang W.; Wang Z.; Yuan Y.; Congenital myasthenic syndrome in China: Genetic and myopathological characterization. Ann Clin Transl Neurol 2021,8(4),898-907","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1055\/s-2004-820996","volume":"35","author":"M\u00fcller J.S.","year":"2004","unstructured":"M\u00fcller J.S.; Petrova S.; Kiefer R.; Stucka R.; K\u00f6nig C.; Baumeister S.K.; Huebner A.; Lochm\u00fcller H.; Abicht A.; Synaptic congenital myasthenic syndrome in three patients due to a novel missense mutation (T441A) of the COLQ gene. Neuropediatrics 2004,35(3),183-189","journal-title":"Neuropediatrics"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3390\/genes11121519","volume":"11","author":"Laforgia N.","year":"2020","unstructured":"Laforgia N.; De Cosmo L.; Palumbo O.; Ranieri C.; Sesta M.; Capodiferro D.; Pantaleo A.; Iapicca P.; Lastella P.; Capozza M.; Schettini F.; Bukvic N.; Bagnulo R.; Resta N.; The first case of congenital myasthenic syndrome caused by a large homozygous deletion in the C-terminal region of COLQ (collagen like tail subunit of asymmetric acetylcholinesterase) protein. Genes (Basel) 2020,11(12),1519","journal-title":"Genes (Basel)"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.nmd.2017.11.013","volume":"28","author":"Durmus H.","year":"2018","unstructured":"Durmus H.; Shen X.M.; Serdaroglu-Oflazer P.; Kara B.; Parman-Gulsen Y.; Ozdemir C.; Brengman J.; Deymeer F.; Engel A.G.; Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term follow-up. Neuromuscul Disord 2018,28(4),315-322","journal-title":"Neuromuscul Disord"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"982434","DOI":"10.3389\/fphar.2022.982434","volume":"13","author":"Ceccanti M.","year":"2022","unstructured":"Ceccanti M.; Libonati L.; Ruffolo G.; Cifelli P.; Moret F.; Frasca V.; Palma E.; Inghilleri M.; Cambieri C.; Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study. Front Pharmacol 2022,13,982434","journal-title":"Front Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1042\/ETLS20180100","volume":"3","author":"Thompson R.","year":"2019","unstructured":"Thompson R.; Bonne G.; Missier P.; Lochm\u00fcller H.; Targeted therapies for congenital myasthenic syndromes: Systematic review and steps towards a treatabolome. Emerg Top Life Sci 2019,3(1),19-37","journal-title":"Emerg Top Life Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.nmd.2011.09.002","volume":"22","author":"Wargon I.","year":"2012","unstructured":"Wargon I.; Richard P.; Kuntzer T.; Sternberg D.; Nafissi S.; Gaudon K.; Lebail A.; Bauche S.; Hanta\u00ef D.; Fournier E.; Eymard B.; Stojkovic T.; Long-term follow-up of patients with congenital myasthenic syndrome caused by COLQ mutations. Neuromuscul Disord 2012,22(4),318-324","journal-title":"Neuromuscul Disord"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0301-0082(93)90040-Y","volume":"41","author":"Massouli\u00e9 J.","year":"1993","unstructured":"Massouli\u00e9 J.; Pezzementi L.; Bon S.; Krejci E.; Vallette F.M.; Molecular and cellular biology of cholinesterases. Prog Neurobiol 1993,41(1),31-91","journal-title":"Prog Neurobiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.pediatrneurol.2014.03.012","volume":"51","author":"Matlik H.N.","year":"2014","unstructured":"Matlik H.N.; Milhem R.M.; Saadeldin I.Y.; Al-Jaibeji H.S.; Al-Gazali L.; Ali B.R.; Clinical and molecular analysis of a novel COLQ missense mutation causing congenital myasthenic syndrome in a Syrian family. Pediatr Neurol 2014,51(1),165-169","journal-title":"Pediatr Neurol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3389\/fnmol.2020.00154","volume":"13","author":"Huang K.","year":"2020","unstructured":"Huang K.; Li J.; Ito M.; Takeda J.I.; Ohkawara B.; Ogi T.; Masuda A.; Ohno K.; Gene expression profile at the motor endplate of the neuromuscular junction of fast-twitch muscle. Front Mol Neurosci 2020,13,154","journal-title":"Front Mol Neurosci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1523\/JNEUROSCI.4374-09.2010","volume":"30","author":"Sigoillot S.M.","year":"2010","unstructured":"Sigoillot S.M.; Bourgeois F.; Lambergeon M.; Strochlic L.; Legay C.; ColQ controls postsynaptic differentiation at the neuromuscular junction. J Neurosci 2010,30(1),13-23","journal-title":"J Neurosci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/brain\/awm325","volume":"131","author":"Mihaylova V.","year":"2008","unstructured":"Mihaylova V.; M\u00fcller J.S.; Vilchez J.J.; Salih M.A.; Kabiraj M.M.; D\u2019Amico A.; Bertini E.; W\u00f6lfle J.; Schreiner F.; Kurlemann G.; Rasic V.M.; Siskova D.; Colomer J.; Herczegfalvi A.; Fabriciova K.; Weschke B.; Scola R.; Hoellen F.; Schara U.; Abicht A.; Lochm\u00fcller H.; Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain 2008,131(3),747-759","journal-title":"Brain"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12031-009-9229-0","volume":"40","author":"Engel A.G.","year":"2010","unstructured":"Engel A.G.; Shen X.M.; Selcen D.; Sine S.M.; What have we learned from the congenital myasthenic syndromes. J Mol Neurosci 2010,40(1-2),143-153","journal-title":"J Mol Neurosci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1113\/jphysiol.1973.sp010248","volume":"231","author":"Katz B.","year":"1973","unstructured":"Katz B.; Miledi R.; The binding of acetylcholine to receptors and its removal from the synaptic cleft. J Physiol 1973,231(3),549-574","journal-title":"J Physiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ana.410010403","volume":"1","author":"Engel A.G.","year":"1977","unstructured":"Engel A.G.; Lambert E.H.; Gomez M.R.; A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release. Ann Neurol 1977,1(4),315-330","journal-title":"Ann Neurol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1113\/jphysiol.1957.sp005838","volume":"138","author":"Katz B.","year":"1957","unstructured":"Katz B.; Thesleff S.; A study of the \u2018desensitization\u2019 produced by acetylcholine at the motor end-plate. J Physiol 1957,138(1),63-80","journal-title":"J Physiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"9654","DOI":"10.1073\/pnas.95.16.9654","volume":"95","author":"Ohno K.","year":"1998","unstructured":"Ohno K.; Brengman J.; Tsujino A.; Engel A.G.; Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. Proc Natl Acad Sci USA 1998,95(16),9654-9659","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/1531-8249(200002)47:2<162::AID-ANA5>3.0.CO;2-Q","volume":"47","author":"Ohno K.","year":"2000","unstructured":"Ohno K.; Engel A.G.; Brengman J.M.; Shen X.M.; Heidenreich F.; Vincent A.; Milone M.; Tan E.; Demirci M.; Walsh P.; Nakano S.; Akiguchi I.; The spectrum of mutations causing end-plate acetylcholinesterase deficiency. Ann Neurol 2000,47(2),162-170","journal-title":"Ann Neurol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/WNL.58.4.603","volume":"58","author":"Shapira Y.A.","year":"2002","unstructured":"Shapira Y.A.; Sadeh M.E.; Bergtraum M.P.; Tsujino A.; Ohno K.; Shen X.M.; Brengman J.; Edwardson S.; Matoth I.; Engel A.G.; Three novel COLQ mutations and variation of phenotypic expressivity due to G240X. Neurology 2002,58(4),603-609","journal-title":"Neurology"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1086\/302059","volume":"63","author":"Donger C.","year":"1998","unstructured":"Donger C.; Krejci E.; Pou Serradell A.; Eymard B.; Bon S.; Nicole S.; Chateau D.; Gary F.; Fardeau M.; Massouli\u00e9 J.; Guicheney P.; Mutation in the human acetylcholinesterase-associated collagen gene, COLQ, is responsible for congenital myasthenic syndrome with end-plate acetylcholinesterase deficiency (Type Ic). Am J Hum Genet 1998,63(4),967-975","journal-title":"Am J Hum Genet"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"761636","DOI":"10.3389\/fneur.2021.761636","volume":"12","author":"Huang K.","year":"2021","unstructured":"Huang K.; Bi F.F.; Yang H.; A systematic review and meta-analysis of the prevalence of congenital myopathy. Front Neurol 2021,12,761636","journal-title":"Front Neurol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"718","DOI":"10.2174\/1570159X18666200729092332","volume":"19","author":"Huang K.","year":"2021","unstructured":"Huang K.; Luo Y.B.; Bi F.F.; Yang H.; Pharmacological strategy for congenital myasthenic syndrome with CHRNE mutations: A meta-analysis of case reports. Curr Neuropharmacol 2021,19(5),718-729","journal-title":"Curr Neuropharmacol"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1080\/21678421.2021.1990345","volume":"23","author":"Shi G.","year":"2021","unstructured":"Shi G.; Shao S.; Zhou J.; Huang K.; Bi F.F.; Urinary p75(ECD) levels in patients with amyotrophic lateral sclerosis: A meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener 2021,23(5-6),438-445","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000524734","volume":"56","author":"Liao Q.","year":"2022","unstructured":"Liao Q.; Zhang Y.; He J.; Huang K.; Global prevalence of myotonic dystrophy: An updated systematic review and meta-analysis. Neuroepidemiology 2022,56(3),163-173","journal-title":"Neuroepidemiology"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"Moher D.","year":"2009","unstructured":"Moher D.; Liberati A.; Tetzlaff J.; Altman D.G.; Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009,6(7),e1000097","journal-title":"PLoS Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"Murad M.H.","year":"2018","unstructured":"Murad M.H.; Sultan S.; Haffar S.; Bazerbachi F.; Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 2018,23(2),60-63","journal-title":"BMJ Evid Based Med"},{"key":"ref=37","first-page":"65","volume":"8","author":"Al-Muhaizea M.A.","year":"2017","unstructured":"Al-Muhaizea M.A.; Al-Mobarak S.B.; COLQ-mutant congenital myasthenic syndrome with microcephaly: A unique case with literature review. Transl Neurosci 2017,8,65-69","journal-title":"Transl Neurosci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1212\/WNL.0000000000001396","volume":"84","author":"Al-Shahoumi R.","year":"2015","unstructured":"Al-Shahoumi R.; Brady L.I.; Schwartzentruber J.; Tarnopolsky M.A.; Two cases of congenital myasthenic syndrome with vocal cord paralysis. Neurology 2015,84(12),1281-1282","journal-title":"Neurology"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.pediatrneurol.2012.02.003","volume":"46","author":"Guven A.","year":"2012","unstructured":"Guven A.; Demirci M.; Anlar B.; Recurrent COLQ mutation in congenital myasthenic syndrome. Pediatr Neurol 2012,46(4),253-256","journal-title":"Pediatr Neurol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/CND.0000000000000160","volume":"18","author":"Padmanabha H.","year":"2017","unstructured":"Padmanabha H.; Saini A.G.; Sankhyan N.; Singhi P.; COLQ-related congenital myasthenic syndrome and response to salbutamol therapy. J Clin Neuromuscul Dis 2017,18(3),162-163","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jocn.2019.12.007","volume":"72","author":"Tay C.G.","year":"2020","unstructured":"Tay C.G.; Fong C.Y.; Li L.; Ganesan V.; Teh C.M.; Gan C.S.; Thong M.K.; Congenital myasthenic syndrome with novel pathogenic variants in the COLQ gene associated with the presence of antibodies to acetylcholine receptors. J Clin Neurosci 2020,72,468-471","journal-title":"J Clin Neurosci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4103\/0028-3886.310105","volume":"69","author":"Prabhudesai S.P.","year":"2021","unstructured":"Prabhudesai S.P.; Pallithanam J.J.; Naik N.; Gauns S.; COLQ-related congenital myasthenic syndrome in a child from Western India. Neurol India 2021,69(1),228-229","journal-title":"Neurol India"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.nmd.2020.12.002","volume":"31","author":"Vidanagamage A.","year":"2021","unstructured":"Vidanagamage A.; Gooneratne I.K.; Nandasiri S.; Gunaratne K.; Fernando A.; Maxwell S.; Cossins J.; Beeson D.; Chang T.; A rare mutation in the COLQ gene causing congenital myasthenic syndrome with remarkable improvement to fluoxetine: A case report. Neuromuscul Disord 2021,31(3),246-248","journal-title":"Neuromuscul Disord"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.nmd.2020.08.362","volume":"30","author":"Pattrakornkul N.","year":"2020","unstructured":"Pattrakornkul N.; Ittiwut C.; Boonsimma P.; Boonyapisit K.; Khongkhatithum C.; Sanmaneechai O.; Suphapeetiporn K.; Shotelersuk V.; Congenital myasthenic syndromes in the Thai population: Clinical findings and novel mutations. Neuromuscul Disord 2020,30(10),851-858","journal-title":"Neuromuscul Disord"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s13760-013-0179-5","volume":"113","author":"Duran G.S.","year":"2013","unstructured":"Duran G.S.; Uzunhan T.A.; Ekici B.; \u00c7\u0131tak A.; Ayd\u0131nl\u0131 N.; \u00c7al\u0131\u015fkan M.; Severe scoliosis in a patient with COLQ mutation and congenital myasthenic syndrome: A clue for diagnosis. Acta Neurol Belg 2013,113(4),531-532","journal-title":"Acta Neurol Belg"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5734\/JGM.2020.17.2.73","volume":"17","author":"Cho A.","year":"2020","unstructured":"Cho A.; Kim S.Y.; Lee J.S.; Lim B.C.; Kim H.; Hwang H.; Chae J-H.; Wide heterogeneity of congenital myasthenic syndromes: Analysis of clinical experience in a tertiary center. J Genet Med 2020,17(2),73-78","journal-title":"J Genet Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/s0960-8966(02)00243-2","volume":"13","author":"Ishigaki K.","year":"2003","unstructured":"Ishigaki K.; Nicolle D.; Krejci E.; Leroy J.P.; Koenig J.; Fardeau M.; Eymard B.; Hanta\u00ef D.; Two novel mutations in the COLQ gene cause endplate acetylcholinesterase deficiency. Neuromuscul Disord 2003,13(3),236-244","journal-title":"Neuromuscul Disord"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.pediatrneurol.2012.04.022","volume":"47","author":"Chan S.H.S.","year":"2012","unstructured":"Chan S.H.S.; Wong V.C.N.; Engel A.G.; Neuromuscular junction acetylcholinesterase deficiency responsive to albuterol. Pediatr Neurol 2012,47(2),137-140","journal-title":"Pediatr Neurol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1111\/j.1469-8749.2010.03663.x","volume":"52","author":"Yeung W.L.","year":"2010","unstructured":"Yeung W.L.; Lam C.W.; Ng P.C.; Intra-familial variation in clinical manifestations and response to ephedrine in siblings with congenital myasthenic syndrome caused by novel COLQ mutations. Dev Med Child Neurol 2010,52(10),e243-e244","journal-title":"Dev Med Child Neurol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1177\/0883073820987755","volume":"36","author":"Prior D.E.","year":"2021","unstructured":"Prior D.E.; Ghosh P.S.; Congenital myasthenic syndrome from a single center: Phenotypic and genotypic features. J Child Neurol 2021,36(8),610-617","journal-title":"J Child Neurol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/CND.0000000000000222","volume":"20","author":"Selvam P.","year":"2018","unstructured":"Selvam P.; Arunachal G.; Danda S.; Chapla A.; Sivadasan A.; Alexander M.; Thomas M.M.; Thomas N.J.; Congenital myasthenic syndrome: Spectrum of mutations in an indian cohort. J Clin Neuromuscul Dis 2018,20(1),14-27","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1086\/302551","volume":"65","author":"Ohno K.","year":"1999","unstructured":"Ohno K.; Brengman J.M.; Felice K.J.; Cornblath D.R.; Engel A.G.; Congenital end-plate acetylcholinesterase deficiency caused by a nonsense mutation and an A-->G splice-donor-site mutation at position +3 of the collagenlike-tail-subunit gene (COLQ): how does G at position +3 result in aberrant splicing? Am J Hum Genet 1999,65(3),635-644","journal-title":"Am J Hum Genet"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.nmd.2006.11.010","volume":"17","author":"Schreiner F.","year":"2007","unstructured":"Schreiner F.; Hoppenz M.; Klaeren R.; Reimann J.; Woelfle J.; Novel COLQ mutation 950delC in synaptic congenital myasthenic syndrome and symptomatic heterozygous relatives. Neuromuscul Disord 2007,17(3),262-265","journal-title":"Neuromuscul Disord"},{"key":"ref=54","first-page":"428","volume":"28","author":"Mishra S.","year":"2020","unstructured":"Mishra S.; Girisha K.; Shukla A.; Further delineation of clinical and molecular characteristics of congenital myasthenic syndromes in Indian families. Eur J Hum Genet 2020,28(Suppl. 1),428-428","journal-title":"Eur J Hum Genet"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/humu.22325","volume":"34","author":"Nakata T.","year":"2013","unstructured":"Nakata T.; Ito M.; Azuma Y.; Otsuka K.; Noguchi Y.; Komaki H.; Okumura A.; Shiraishi K.; Masuda A.; Natsume J.; Kojima S.; Ohno K.; Mutations in the C-terminal domain of ColQ in endplate acetylcholinesterase deficiency compromise ColQ-MuSK interaction. Hum Mutat 2013,34(7),997-1004","journal-title":"Hum Mutat"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00439-013-1391-3","volume":"133","author":"Arredondo J.","year":"2014","unstructured":"Arredondo J.; Lara M.; Ng F.; Gochez D.A.; Lee D.C.; Logia S.P.; Nguyen J.; Maselli R.A.; COOH-terminal collagen Q (COLQ) mutants causing human deficiency of endplate acetylcholinesterase impair the interaction of ColQ with proteins of the basal lamina. Hum Genet 2014,133(5),599-616","journal-title":"Hum Genet"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"679342","DOI":"10.3389\/fped.2021.679342","volume":"9","author":"Luo X.","year":"2021","unstructured":"Luo X.; Wang C.; Lin L.; Yuan F.; Wang S.; Wang Y.; Wang A.; Wang C.; Wu S.; Lan X.; Xu Q.; Yin R.; Cheng H.; Zhang Y.; Xi J.; Zhang J.; Sun X.; Yan J.; Zeng F.; Chen Y.; Mechanisms of congenital myasthenia caused by three mutations in the COLQ gene. Front Pediatr 2021,9,679342","journal-title":"Front Pediatr"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s13760-019-01246-9","volume":"121","author":"G\u00fcl Mert G.","year":"2021","unstructured":"G\u00fcl Mert G.; \u00d6zcan N.; Herg\u00fcner \u00d6.; Altunba\u015fak \u015e.; Incecik F.; Bi\u015fgin A.; Ceylaner S.; Congenital myasthenic syndrome in Turkey: Clinical and genetic features in the long-term follow-up of patients. Acta Neurol Belg 2021,121(2),529-534","journal-title":"Acta Neurol Belg"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jocn.2017.10.084","volume":"48","author":"Ding Q.","year":"2018","unstructured":"Ding Q.; Shen D.; Dai Y.; Hu Y.; Guan Y.; Liu M.; Cui L.; Mechanism hypotheses for the electrophysiological manifestations of two cases of endplate acetylcholinesterase deficiency related congenital myasthenic syndrome. J Clin Neurosci 2018,48,229-232","journal-title":"J Clin Neurosci"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/age.12350","volume":"46","author":"Gandolfi B.","year":"2015","unstructured":"Gandolfi B.; Grahn R.A.; Creighton E.K.; Williams D.C.; Dickinson P.J.; Sturges B.K.; Guo L.T.; Shelton G.D.; Leegwater P.A.J.; Longeri M.; Malik R.; Lyons L.A.; COLQ variant associated with D evon R ex and S phynx feline hereditary myopathy. Anim Genet 2015,46(6),711-715","journal-title":"Anim Genet"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1212\/01.wnl.0000167132.35865.31","volume":"65","author":"Bestue-Cardiel M.","year":"2005","unstructured":"Bestue-Cardiel M.; de Cabezon-Alvarez A.S.; Capablo-Liesa J.L.; L\u00f3pez-Pis\u00f3n J.; Pe\u00f1a-Segura J.L.; Martin-Martinez J.; Engel A.G.; Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 2005,65(1),144-146","journal-title":"Neurology"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00281-021-00895-4","volume":"43","author":"Lee J.D.","year":"2021","unstructured":"Lee J.D.; Woodruff T.M.; The emerging role of complement in neuromuscular disorders. Semin Immunopathol 2021,43(6),817-828","journal-title":"Semin Immunopathol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/dneu.20891","volume":"72","author":"Dani N.","year":"2012","unstructured":"Dani N.; Broadie K.; Glycosylated synaptomatrix regulation of trans-synaptic signaling. Dev Neurobiol 2012,72(1),2-21","journal-title":"Dev Neurobiol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.1242\/dev.099192","volume":"140","author":"Parkinson W.","year":"2013","unstructured":"Parkinson W.; Dear M.L.; Rushton E.; Broadie K.; N-glycosylation requirements in neuromuscular synaptogenesis. Development 2013,140(24),4970-4981","journal-title":"Development"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1046\/j.1471-4159.1994.62051653.x","volume":"62","author":"Wu D.","year":"1994","unstructured":"Wu D.; Hersh L.B.; Choline acetyltransferase: Celebrating its fiftieth year. J Neurochem 1994,62(5),1653-1663","journal-title":"J Neurochem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13023-019-1025-5","volume":"14","author":"Finsterer J.","year":"2019","unstructured":"Finsterer J.; Congenital myasthenic syndromes. Orphanet J Rare Dis 2019,14(1),57","journal-title":"Orphanet J Rare Dis"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"111357","DOI":"10.1016\/j.biopha.2021.111357","volume":"137","author":"Bragato C.","year":"2021","unstructured":"Bragato C.; Blasevich F.; Ingenito G.; Mantegazza R.; Maggi L.; Therapeutic efficacy of 3,4-Diaminopyridine phosphate on neuromuscular junction in Pompe disease. Biomed Pharmacother 2021,137,111357","journal-title":"Biomed Pharmacother"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.resp.2007.08.003","volume":"160","author":"Ionno M.","year":"2008","unstructured":"Ionno M.; Moyer M.; Pollarine J.; van Lunteren E.; Inotropic effects of the K+ channel blocker 3,4-diaminopyridine on fatigued diaphragm muscle. Respir Physiol Neurobiol 2008,160(1),45-53","journal-title":"Respir Physiol Neurobiol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1517\/17460441.2014.907790","volume":"9","author":"Perez-Caballero L.","year":"2014","unstructured":"Perez-Caballero L.; Torres-Sanchez S.; Bravo L.; Mico J.A.; Berrocoso E.; Fluoxetine: a case history of its discovery and preclinical development. Expert Opin Drug Discov 2014,9(5),567-578","journal-title":"Expert Opin Drug Discov"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3389\/fneur.2019.00516","volume":"10","author":"Huang K.","year":"2019","unstructured":"Huang K.; Luo Y.B.; Yang H.; Autoimmune channelopathies at neuromuscular junction. Front Neurol 2019,10,516","journal-title":"Front Neurol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"CD010028","DOI":"10.1002\/14651858.CD010028.pub2","volume":"2014","author":"Vrinten C.","year":"2014","unstructured":"Vrinten C.; van der Zwaag A.M.; Weinreich S.S.; Scholten R.J.P.M.; Verschuuren J.J.G.M.; Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes. Cochrane Libr 2014,2014(12),CD010028","journal-title":"Cochrane Libr"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1001\/jama.1930.27120410003009c","volume":"94","author":"Edgeworth H.","year":"1930","unstructured":"Edgeworth H.; A report of progress on the use of ephedrine in a case of myasthenia gravis. JAMA 1930,94(15),1136","journal-title":"JAMA"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1056\/NEJM200012213432502","volume":"343","author":"Haller C.A.","year":"2000","unstructured":"Haller C.A.; Benowitz N.L.; Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000,343(25),1833-1838","journal-title":"N Engl J Med"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1212\/WNL.0b013e3181dd43bf","volume":"74","author":"Lashley D.","year":"2010","unstructured":"Lashley D.; Palace J.; Jayawant S.; Robb S.; Beeson D.; Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology 2010,74(19),1517-1523","journal-title":"Neurology"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/brain\/awm068","volume":"130","author":"M\u00fcller J.S.","year":"2007","unstructured":"M\u00fcller J.S.; Herczegfalvi A.; Vilchez J.J.; Colomer J.; Bachinski L.L.; Mihaylova V.; Santos M.; Schara U.; Deschauer M.; Shevell M.; Poulin C.; Dias A.; Soudo A.; Hietala M.; A\u00e4rimaa T.; Krahe R.; Karcagi V.; Huebner A.; Beeson D.; Abicht A.; Lochm\u00fcller H.; Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Brain 2007,130(6),1497-1506","journal-title":"Brain"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1001\/jamaneurol.2013.5590","volume":"71","author":"Witting N.","year":"2014","unstructured":"Witting N.; Vissing J.; Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome. JAMA Neurol 2014,71(3),350-354","journal-title":"JAMA Neurol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1002\/ajmg.a.61579","volume":"182","author":"Maselli R.A.","year":"2020","unstructured":"Maselli R.A.; Linden H.; Ferns M.; Recessive congenital myasthenic syndrome caused by a homozygous mutation inSYT2 altering a highly conserved C\u2010terminal amino acid sequence. Am J Med Genet A 2020,182(7),1744-1749","journal-title":"Am J Med Genet A"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"e12743","DOI":"10.1111\/nan.12743","volume":"48","author":"Malfatti E.","year":"2022","unstructured":"Malfatti E.; Catchpool T.; Nouioua S.; Sihem H.; Fournier E.; Carlier R.Y.; Cardone N.; Davis M.R.; Laing N.G.; Sternberg D.; Ravenscroft G. A; TOR1AIP1 variant segregating with an early onset limb girdle myasthenia\u2014Support for the role of LAP1 in NMJ function and disease. Neuropathol Appl Neurobiol 2022,48(1),e12743","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/nan.12617","volume":"46","author":"Lee C.Y.","year":"2020","unstructured":"Lee C.Y.; Petkova M.; Morales-Gonzalez S.; Gimber N.; Schmoranzer J.; Meisel A.; B\u00f6hmerle W.; Stenzel W.; Schuelke M.; Schwarz J.M.; A spontaneous missense mutation in the chromodomain helicase DNA\u2010binding protein 8 (CHD8) gene: a novel association with congenital myasthenic syndrome. Neuropathol Appl Neurobiol 2020,46(6),588-601","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/JND-170293","volume":"5","author":"Clausen L.","year":"2018","unstructured":"Clausen L.; Cossins J.; Beeson D.; Beta-2 adrenergic receptor agonists enhance AChR clustering in C2C12 myotubes: Implications for therapy of myasthenic disorders. J Neuromuscul Dis 2018,5(2),231-240","journal-title":"J Neuromuscul Dis"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/hmg\/ddy062","volume":"27","author":"McMacken G.","year":"2018","unstructured":"McMacken G.; Cox D.; Roos A.; M\u00fcller J.; Whittaker R.; Lochm\u00fcller H.; The beta-adrenergic agonist salbutamol modulates neuromuscular junction formation in zebrafish models of human myasthenic syndromes. Hum Mol Genet 2018,27(9),1556-1564","journal-title":"Hum Mol Genet"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1093\/hmg\/ddz059","volume":"28","author":"McMacken G.M.","year":"2019","unstructured":"McMacken G.M.; Spendiff S.; Whittaker R.G.; O\u2019Connor E.; Howarth R.M.; Boczonadi V.; Horvath R.; Slater C.R.; Lochm\u00fcller H.; Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome. Hum Mol Genet 2019,28(14),2339-2351","journal-title":"Hum Mol Genet"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mus.22176","volume":"44","author":"Liewluck T.","year":"2011","unstructured":"Liewluck T.; Selcen D.; Engel A.G.; Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle Nerve 2011,44(5),789-794","journal-title":"Muscle Nerve"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1152\/physrev.00028.2007","volume":"88","author":"Lynch G.S.","year":"2008","unstructured":"Lynch G.S.; Ryall J.G.; Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 2008,88(2),729-767","journal-title":"Physiol Rev"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0024-3205(92)90374-X","volume":"50","author":"Kim Y.S.","year":"1992","unstructured":"Kim Y.S.; Sainz R.D.; \u03b2-adrenergic agonists and hypertrophy of skeletal muscles. Life Sci 1992,50(6),397-407","journal-title":"Life Sci"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.nmd.2014.11.017","volume":"25","author":"Guo Y.","year":"2015","unstructured":"Guo Y.; Menezes M.J.; Menezes M.P.; Liang J.; Li D.; Riley L.G.; Clarke N.F.; Andrews P.I.; Tian L.; Webster R.; Wang F.; Liu X.; Shen Y.; Thorburn D.R.; Keating B.J.; Engel A.; Hakonarson H.; Christodoulou J.; Xu X.; Delayed diagnosis of congenital myasthenia due to associated mitochondrial enzyme defect. Neuromuscul Disord 2015,25(3),257-261","journal-title":"Neuromuscul Disord"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X21666230126145652","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/213188\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X21666230126145652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:25:34Z","timestamp":1693700734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/213188\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":86,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x21666230126145652","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}